Anti-glioma response of autologous T cells stimulated by autologous dendritic cells electrofused with CD133+ or CD133- glioma cells

被引:7
|
作者
Qin, Kun [1 ]
Tian, Ge [2 ]
Li, Peng [1 ]
Chen, Qiang [1 ]
Zhang, Run [1 ]
Ke, Yi-quan [1 ]
Xiao, Zhi-cheng [3 ]
Jiang, Xiao-dan [1 ]
机构
[1] So Med Univ, Zhujiang Hosp, Inst Neurosurg, Key Lab Brain Funct Repair & Regenerat Guangdong, Guangzhou 510282, Guangdong, Peoples R China
[2] So Med Univ, Nanfang Hosp, Dept Neurol, Guangzhou 510515, Guangdong, Peoples R China
[3] Monash Univ, MISCL, Clayton, Vic 3800, Australia
关键词
Glioma stem like cells; CD133; Dentritic cells; Cell fusion; Tumor vaccine; CANCER STEM-CELLS; INITIATING CELLS; VACCINATION; BIOLOGY; MOUSE;
D O I
10.1016/j.jneuroim.2011.11.001
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Glioma, the most common tumor of the central nervous system (CNS), currently results in a high rate of morbidity and mortality. The expression of CD133, a stem-like cell marker expressed in the glioma cells, is believed to lead to tumorigenesis in the human brain. Thus, it is necessary to find a proper method to specifically kill the CD133(+) glioma cells. Dendritic cell (DC)/tumor hybrids are proven to be able to induce an effective immune response, leading to killing of glioma cells in vitro. We isolated CD133(+) cells from a population of primary glioma cells, and cultured autologous DCs and T cells at the same time. Next, we electrofused the DCs with the CD133(+) glioma cells and with CD133 - ones, in order to explore a new strategy for glioma therapy. We then exposed the T cells to five separate groups of cells: DC/CD133(+) hybrids, DC/CD133(-) hybrids, DCs alone, unsorted glioma cells alone and mixed DCs-glioma cells. A cytotoxicity assay showed that T cells stimulated by either type of hybrid were able to kill cultured autologous glioma cells significantly more effectively than those stimulated by the other three cell types (P<0.05). The amounts of IFN-gamma secreted by T cells stimulated by the two types of fused cells were obviously increased compared to those stimulated by the other three cell types (P<0.05). However, no significant differences were noted between the effects of the two hybrids, neither in the cytotoxicity assay nor in the IFN-gamma release assay (P > 0.05). Therefore, both DC/CD133(+) and DC/CD133(-) hybrids can cause significant T cell immune responses in vitro. There were no significant differences between the immune responses caused by the two types of hybrids. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:9 / 15
页数:7
相关论文
共 50 条
  • [1] Differential characteristics of CD133+ and CD133- Jurkat cells
    Anbarlou, Azadeh
    Atashi, Amir
    Soleimani, Masoud
    AkhavanRahnama, Mahshid
    Bohloli, Mahbobeh
    Mossahebi-Mohammadi, Majid
    IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL, 2015, 51 (06) : 556 - 561
  • [2] CD133+ and CD133- Cancer stem cells in glioblastoma
    Beier, D.
    Hau, P.
    Proescholdt, M.
    Lohmeier, A.
    Aigner, L.
    Brawanski, A.
    Bogdahn, U.
    Beier, C. P.
    NEURO-ONCOLOGY, 2006, 8 (04) : 317 - 317
  • [3] Hexokinase II in CD133+ and CD133- Hepatoma BEL-7402 Cells
    Gong, Lei
    Cui, Zhuqingqing
    Yu, Xin
    Wei, Yuhua
    Peng, Jirun
    Leng, Xisheng
    PATHOLOGY & ONCOLOGY RESEARCH, 2012, 18 (02) : 377 - 381
  • [4] Daoy medulloblastoma cells that express CD133 are radioresistant relative to CD133- cells, and the CD133+ sector is enlarged by hypoxia
    Blazek, Ed R.
    Foutch, Jennifer L.
    Maki, Guitta
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 67 (01): : 1 - 5
  • [5] Expression profiling of CD133+ and CD133- epithelial cells from human prostate
    Shepherd, Christopher J.
    Rizzo, Sian
    Ledaki, Ioanna
    Davies, Melissa
    Brewer, Daniel
    Attard, Gerhardt
    de Bono, Johann
    Hudson, David L.
    PROSTATE, 2008, 68 (09): : 1007 - 1024
  • [6] CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors
    Shmelkov, Sergey V.
    Butler, Jason M.
    Hooper, Andrea T.
    Hormigo, Adilia
    Kushner, Jared
    Milde, Till
    St. Clair, Ryan
    Baljevic, Muhamed
    White, Ian
    Jin, David K.
    Chadburn, Amy
    Murphy, Andrew J.
    Valenzuela, David M.
    Gale, Nicholas W.
    Thurston, Gavin
    Yancopoulos, George D.
    D'Angelica, Michael
    Kemeny, Nancy
    Lyden, David
    Rafii, Shahin
    JOURNAL OF CLINICAL INVESTIGATION, 2008, 118 (06): : 2111 - 2120
  • [7] Characterization of megakaryocytes progenitor cells differentiated from umbilical cord blood CD133+ and CD133- cells
    Goodarzi, A.
    Pour, M. Aghaeii
    Firozi, A.
    Pourfathaollah, A.
    Tabatabaeian, A.
    Vaeli, S.
    Niroomanesh, S.
    Ebtekar, M.
    Kheirandish, M.
    VOX SANGUINIS, 2006, 91 : 245 - 245
  • [8] Iterative sorting reveals CD133+ and CD133- melanoma cells as phenotypically distinct populations
    Carole Grasso
    Matthew Anaka
    Oliver Hofmann
    Ramakrishna Sompallae
    Kate Broadley
    Winston Hide
    Michael V. Berridge
    Jonathan Cebon
    Andreas Behren
    Melanie J. McConnell
    BMC Cancer, 16
  • [9] Ex vivo expansion of megakaryocytes progenitor cells from umbilical cord blood CD133+ and CD133- cells
    Kheirandish, M.
    Firozi, A.
    Pourfathaollah, A.
    Tabatabaeian, A.
    Niroomanesh, S.
    Goodarzi, A.
    Vaeli, S.
    VOX SANGUINIS, 2006, 91 : 245 - 245
  • [10] Cell cycle analysis of the CD133+ and CD133- cells isolated from umbilical cord blood
    Grskovic, B
    Ruzicka, K
    Karimi, A
    Qujeq, D
    Müller, MM
    CLINICA CHIMICA ACTA, 2004, 343 (1-2) : 173 - 178